Pfizer Inc. (PFE)
The drug price deal between Pfizer and the Trump administration was built on down-to-the-wire team negotiations, building on a relationship between CEO Albert Bourla and President Trump
Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.
Heard on the Street: Pfizer's accord on price cuts with President Trump clears a cloud over the whole pharma industry
The company's accord with the president clears a cloud over the whole sector.
Top 3 Dividend Achievers for October: High Yields, Growth Ahead
These stocks are attractive investments due to their proven models, stable cash flow, and ability to sustain capital returns, which may also lead to share price increases and capital gains.
Pfizer's Art Of The Deal
President Trump and Pfizer announced a deal to cut drug pricing yeseterday. And it looks like the pharmaceutical giant got the better end of it.
This 6.75%-Yielding Dividend Stock Can Gain 33%
Pfizer (NYSE:PFE) shares are finally starting to attract attention after gaining close to 7% in a single trading session on news that it's reached a pricing deal with the Trump administration.
Pfizer Drug-Pricing Deal: More Upside For PFE Stock?
Pfizer stock (NYSE: PFE) offers a compelling investment opportunity at its current price of around $25, supported by attractive valuations and recent policy changes that may present further upside potential.
Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
President Donald Trump's long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer. Trump's agreement with Pfizer included a three-year exemption from pharmaceutical-specific tariffs, so long as the firm further invests in domestic manufacturing.
Drug pricing, politics and the cost of doing business in the US
Drug pricing politics in Washington just took a sharp turn. Pfizer Inc (NYSE:PFE, ETR:PFE) has struck a deal with President Trump to support his “Most Favoured Nation” (MFN) plan, which links US drug prices to those in other major markets.
European healthcare stocks surge as U.S. Pfizer deal reduces some uncertainty
European healthcare stocks jumped on Wednesday, a day after Pfizer and U.S. President Donald Trump said the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program in exchange for tariff relief.
Explainer: What does Trump's deal with Pfizer mean for drug prices?
President Donald Trump, who has long argued that the U.S. pays more than it should for prescription medicines, on Tuesday said Pfizer had agreed to cut prices for drugs it sells to the Medicaid program for low-income Americans and to ensure the U.S. would not pay more for new medicines than other high-income nations. Trump said he expects other drugmakers to follow suit.
Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug
Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.
Pfizer found a way to boost its ailing stock — agree with Trump on drug pricing
Pfizer's stock surged after CEO Albert Bourla announces an agreement with the Trump administration aimed at lowering drug prices in the U.S. and removing tariff uncertainty.
